Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:22 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1007
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Colorado Anschutz, Aurora, CO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 817–828 of 1,007 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting Phase 4 Interventional

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

NCT07424378
Site status not listed — check the official record
View directory record Official record
Conditions
Frostbite
Interventions
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Knee Osteoarthritis Rehabilitation Through Rotational Inertia

NCT07424352
Status at this site: Recruiting
View directory record Official record
Conditions
Knee Arthritis, Osteoarthritis
Interventions
Eccentric resistance training
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Recruiting No phase listed Observational

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

NCT01580982
Status at this site: Recruiting
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Active, not recruiting Phase 3 Interventional

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280
Site status not listed — check the official record
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Bonita, California • Escondido, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of High Altitude on AMPK Activation

NCT02391519
Status at this site: Recruiting
View directory record Official record
Conditions
Pregnancy, IUGR, Preeclampsia
Interventions
Collection of myometrial, cord blood, and placental tissue samples
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Study of Placental Function in Healthy and Pathological Pregnancies

NCT02321007
Status at this site: Recruiting
View directory record Official record
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Recruiting Phase 3 Interventional

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic HER2-positive Breast Cancer
Interventions
Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241
Site status not listed — check the official record
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Beverly Hills, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Active, not recruiting Phase 2 Interventional

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951
Site status not listed — check the official record
View directory record Official record
Conditions
Melanoma
Interventions
cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Recruiting No phase listed Observational

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

NCT06837181
Status at this site: Recruiting
View directory record Official record
Conditions
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes, Diabetes, Retinopathy, Neuropathy, Nephropathy, Blood Pressure, Cardiovascular Risk, Microvascular
Interventions
observational study
Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 3, 2026, 5:22 PM EST
Active, not recruiting Not applicable Interventional

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

NCT02308085
Site status not listed — check the official record
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Endocrine therapy interruption
Other
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 42 Years · Female only
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
103
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 3, 2026, 5:22 PM EST

About this University of Colorado Anschutz institution page

What this page lists
ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.